Congreso de la American Academy of Dermatology
Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil®-1 study
Elewski B, et al. Póster 32924
Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil®-1 study
Burden D, et al. Póster 33007
Clinically significant improvements in patient-reported outcomes (PROs) in patients with a generalized pustular psoriasis (GPP) flare treated with spesolimab
Navarini A, et al. Póster 33005
Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scale for assessing severity of GPP
Burden D, et al. Póster 33547
Prevalence, comorbidities, and mortality of generalized pustular psoriasis (GPP): A literature review
Viguier M, et al. Póster 33011
SPE1167.11.2022